On November 18, 2026, the General Health Insurance General Directorate of Turkey's Social Security Institution (Sosyal Güvenlik Kurumu, SGK) published Announcement 2026/45 (Duyuru 2026/45) on the List of Reimbursable Pharmaceuticals (Bedeli Ödenecek İlaçlar Listesi). The one-page notice states that the amendments made under Article 12 of the Drug Reimbursement Regulation (İlaç Geri Ödeme Yönetmeliği) and under sections 4.4.1 and 4.4.2 of the Health Implementation Communiqué (Sağlık Uygulama Tebliği, SUT), adopted under Law No. 5510, enter into force on November 20, 2026.
Marketing authorisation holders of SETINOX 4 mg/ml oral solution, newly added to EK-4/A, holders of CORBINAL 250 mg and ESODAX 400 mg, reactivated on that annex, holders of the barcode-amended lines, Turkish community and hospital pharmacies that bill these products to SGK, and pharmaceutical wholesalers supplying the EK-4/A list must align barcodes, equivalent-group codes and SGK reimbursement status, and invoice only the codes that the November 20, 2026 list accepts, by November 20, 2026, or from that date a product missing from the updated list, or billed under a superseded barcode, is not reimbursed by SGK. EK-4/A is the annex of the List of Reimbursable Pharmaceuticals (Bedeli Ödenecek İlaçlar Listesi) on which the Social Security Institution records the medicines it reimburses.
What does Announcement 2026/45 change on EK-4/A?
The annex published with the SGK announcement page is three sheets, not a general rewrite of the SUT.
| Annex | What the sheet does | Lines | Date on the sheet |
|---|---|---|---|
| Added (EK-1) | SETINOX 4 mg/ml oral solution, 100 ml, A20501, barcode 8699543590110, group E726H, equivalent status | 1 | List entry November 20, 2026 |
| Amended (EK-2) | Existing lines restated, six of them with a new barcode | 77 | November 20, 2026 |
| Reactivated (EK-3) | CORBINAL 250 mg (A09551) and ESODAX 400 mg (A11726) | 2 | Activation November 20, 2026, passive since May 1, 2026 |
SETINOX carries wholesaler discounts of 28, 18, 10 and 0 percent across the four ex-factory bands, and a pharmacy discount of 0 to 2.5 percent. Band tracking starts on November 20, 2026. ATTEX 4 mg/ml oral solution, also 100 ml, is on the amended sheet in the same group, E726H.
Six of the 77 amended lines replace a barcode: ADELEKS 4 mg/2 ml (8685119899022, former 8699541751605), ATARAX 25 mg (8681801092085, former 8699624090058), ATARAX 2 mg/ml syrup (8681801572181, former 8699624570062), NOOTROPIL 200 mg/ml syrup (8681801572105, former 8699624570031), SIPLONE 0.3 percent eye drops (8680199022087, former 8680199611458) and SULPIR 50 mg (8681801152147, former 8699809156678). The other amended lines, including Aspirin 100 mg and 500 mg, Aimafix, Artenak, Atoksilin and Attex, keep the barcode the sheet shows and restate equivalent-group or discount status. The full grid is the 20 November 2026 workbook.
Who has to apply the November 20, 2026 list?
The exposed actors are the marketing authorisation holders of the added, amended and reactivated lines, and the Turkish pharmacies and wholesalers that bill those lines to SGK.
Holders of SETINOX treat November 20, 2026 as the first reimbursable day of A20501. Holders of CORBINAL and ESODAX treat the same day as reactivation: both lines show a passive date of May 1, 2026. CORBINAL returns as equivalent, group E263A. ESODAX returns as price-protected (fiyat korumalı), group E019C, with a special discount of 6 percent on the lower price bands. Pharmacies and wholesalers are exposed wherever they invoice these public numbers.
Obsidian tracks 9 regulatory texts, in force, amended or in preparation, for the Life Sciences and MedTech industry in Turkey, as of November 2026.
What must be aligned before November 20, 2026?
Each holder, pharmacy and wholesaler on these lines has to match its billing file to the workbook before the first invoice dated November 20, 2026.
- Load public number A20501, barcode 8699543590110, for SETINOX 4 mg/ml oral solution, with equivalent group E726H and the four band discounts on the added sheet.
- Switch the six superseded barcodes listed above and stop invoicing the former codes from November 20, 2026.
- Reactivate CORBINAL 250 mg (8699578010447) and ESODAX 400 mg (8699578090883) with the activation date, discount status and equivalent group printed on the third sheet.
- Recheck equivalent-group and discount fields on the other amended lines, including Aspirin, Aimafix, Artenak, Atoksilin and Attex, even where the barcode is unchanged.
- Confirm that pharmacy systems and wholesale distribution records cite the current barcode before a claim is submitted to SGK.
Continuous per-jurisdiction monitoring is what surfaces an SGK list annex of this kind on the day the announcement page goes up.
What is unpaid if the old code is billed?
From November 20, 2026, SGK does not reimburse a product that is missing from the updated EK-4/A list, or a line billed under a superseded barcode. The announcement does not set a separate fine. The blocking effect is the unpaid claim itself, which is the operational consequence for pharmacies and wholesalers and for the holders whose packs still carry the former barcode.
The notice names the Medicines Department of the General Health Insurance General Directorate as the contact unit. It sets no fine and no date after November 20, 2026.
Match each public number to the three sheets, load the six new barcodes, and brief market access and the pharmacy network on the November 20, 2026 effective date. Obsidian keeps the Turkey reimbursement list beside the pricing and marketing authorisation rules.


